JUSTIFICATION FOR SINGLE SOURCE AWARDS IAW FAR 13.106-1

(OVER MICRO-PURCHASE THRESHOLD(\$3.5K) BUT NOT EXCEEDING THE SAT (\$150K))

IAW <u>FAR13.104</u>, COs must promote competition to the maximum extent practicable to obtain supplies and services from the source whose offer is the most advantageous to the Government, considering the administrative cost of the purchase. When competition is not practicable, IAW <u>FAR13.106-1(b)</u>, COs solicit from a single source for purchases not exceeding the simplified acquisition threshold. COs may solicit from one source if the CO determines that the circumstances of the contract action deem only one source reasonably available (e.g., urgency, exclusive licensing agreements, brand-name or industrial mobilization). IAW <u>FAR13.106-3(b)(3)</u>, COs are required to include additional statements explaining the absence of competition (see <u>13.106-1</u> for brand name purchases) if only one source is solicited and the acquisition does not exceed the simplified acquisition threshold (does not apply to an acquisition of utility services available from only one source) or supporting the award decision if other than price-related factors were considered in selecting the supplier. This template when completed can be used to document single source awards IAW <u>FAR13.106-3(b)(3)</u>. Note: Statements such as "only known source" or "only source which can meet the required delivery date" are inadequate to support a sole source purchase.

1. ACQUISITION PLAN ACTION ID:

VA261-16-AP-6783

1A. PROJECT/TASK No. 1B. ESTIMATED AMOUNT:

2. BRIEF DESCRIPTION OF SUPPLIES OR SERVICES REQUIRED AND THE INTENDED USE: MAGNA PURE 96 NUCLEIC ACID EXTRACTOR TO TEST FOR THE ZIKA VIRUS

3. UNIQUE CHARACTERISTICS THAT LIMIT AVAILABILITY TO ONLY ONE SOURCE, WITH THE REASON NO OTHER SUPPLIES OR SERVICES CAN BE USED:

The tests for Zika are new and the Federal Drug Administration has recently issued an Emergency Use Authorization (EUA) for the Trioplex Real-time RT-PCR Assay. This assay is only approved to be run on Roche's Magna Pure 96 analyzer.

4. DESCRIPTION OF MARKET RESEARCH CONDUCTED AND RESULTS OR STATEMENT WHY IT WAS NOT CONDUCTED:

VIP, FBO.gov, Google search, FDA web site.

5. Contracting Officer's Certification: Purchase is approved in accordance with FAR13.106-1(b). I certify that the foregoing justification is accurate and complete to the best of my knowledge and belief. Note: COs are required to make a determination of price reasonableness IAW FAR 13.106-3. See the <u>Commercial Supply and Service SOP</u> for Price Reasonableness templates.

Patricia Benson DN: dc=gov, dc=va, o=internal, ou=people, 0.9.2342.19.200300.100.1.1=patricia Representation Re

Digitally signed by Patricia Benson 616367

ou=people, 0.9.2342.19200300.100.1.1=patricia.bens on@va.gov, cn=Patricia Benson 616367 Date: 2016.09.09 15:09:27 -07'00'

Title: Contracting Officer NCO:21

OFOC SOP Revision 05 Original Date: 03/22/11 Revision 05 Date: 05/02/2016